MEN1 and acute myeloid leukemia: Various menin inhibitors have been developed and investigated in pre-clinical and clinical trials, with revumenib (SNDX-5613) achieving complete remissions in 30% of relapsed or refractory (r/r) AML patients harboring KMT2Ar or NPM1c [7].